Since then, we've made substantial progress in expanding and evolving our pipeline for the benefit of future patients. We have the potential to bring as many new drugs to market in the next five years as we launched over the last 10 years across a greater number of therapeutic areas and m...
A full evaluation of the data from this study is ongoing, and Merck and Eisai will present these results at an upcoming medical meeting. “Locally advanced unresectable or metastatic gastroesophageal adenocarcinoma rema...
known as MSD outside the United States and Canada, today announced the presentation of new data for three investigational medicines in Merck’s diverse and expansive oncology pipeline: vibostolimab (MK-7684), an anti-TIGIT therapy; MK-4830, ...
“Our research at the 2024 ASCO Annual Meeting showcases the advancement of our novel pipeline designed to exploit the major vulnerabilities of cancer, with new data from our lead investigational antibody-drug conjugate and our DNA damage response portfolio,” said Victoria Zazulina, M.D., Head ...
new model for the commercialization path of the company's pipeline in the future,” said Abbisko Chairman Xu Yao-chang. First CSF-1R inhibitor developed in China to enter global trials Internally discovered and developed by Abbisko, pimicotinib is an orally bioavailable, selective, small molecule ...
Our R&D pipeline positions us with a clear focus on strengthening our leadership Strategy & management 5 positions in oncology, neurology, and immunology. During the Covid-19 pandemic, we have been continuously making every effort to proactively handle the situation and minimize the impact of the ...
Merck KGaA, Darmstadt, Germany today announced it will present data on its approved and investigational multiple sclerosis (MS) treatments at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting.
Globally, we have been currently advancing our pipeline across four key modalities. The first modality is the DDR (DNA Damage Response), a significant focus of our research. We are actively developing two assets in this area: an oral ATR inhibitor targeting ataxia telangiectasia and Rad3-related...
With the implementation of Project Integrum, Biocytogen has entered ongoing collaborations with dozens of partners worldwide to produce many first-in-class and/or best-in-class antibody drugs. Biocytogen's pipeline includes 12 core products among which 2 products are in phase II multi-regional ...
psm3mkv: A package to evaluate the fit and efficiency of three state oncology cost-effectiveness model structures bgc-pipelinePublic CEEDesigns.jlPublic A decision-making framework for the cost-efficient design of experiments, balancing the value of acquired experimental evidence and incurred costs....